Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the provided transcript. The company has a net cash position of Rs. 24 billion and maintains a conservative approach to capital allocation. Current capital allocation focuses on acquisitions and organic growth, with no immediate plans to revise dividend policy or increase medical representative deployment. CFO Rajesh Dubey and Sandeep Singh emphasized that if better opportunities arise, the company has resources available, but nothing is planned in the near term. The discussions around capital expenditure primarily focus on b

Any current/future capex/capital investment/strategic investment?

Q1 FY2024 capex was approximately Rs. 78-80 Crores. Annual capex guidance for FY2024 is Rs. 300-350 Crores. Major portion of the capex is allocated for biosimilar investments. The capex guidance includes investments in biosimilars along with other ongoing capital expenditures. No specific mention of new large strategic acquisitions or expansions; company maintains a conservative capital allocation approach. Management open to deploying cash if better acquisition opportunities arise but currently focused on internal investments, especially in biosimilars and CDMO. No expansion in medical repres

Future growth expectations in sales/revenue/volumes?

Domestic business: Expected to deliver high single-digit growth (~8-9%) with a combination of volume recovery and price increases through NRV (net realizable value), especially post Q2 after DPCO price hikes take effect. Chronic therapy segment growing faster than the market with 15.8% YoY growth; expected to contribute positively to margins. Enzene biosimilar and CDMO business projected to grow from Rs.260 Crores in FY2024 (up from Rs.160 Crores last year) with aspirations to double sales over the next couple of years; break-even expected next year. International markets, including the US, sh

Future growth expectations in earnings/operating earnings/profits/EPS?

Alkem Laboratories expects domestic business growth in high single digits for FY2024, with double-digit growth seen as challenging currently. EBITDA margin guidance is maintained at around 16%, with efforts to increase margins by 50 to 100 basis points annually. Enzene (biosimilars and CDMO segment) is projected to grow to around Rs.260-250 Crores revenue for the year, with break-even expected in the next financial year. Cost-saving initiatives are ongoing, with Rs.110 Crores factored into the current budget and medium-term goals aiming for Rs.200 Crores savings. Easing of raw material

Alkem Laboratories LtdQ1 FY24Pharmaceuticals & Biotechnology

Alkem Laboratories Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹5,079P/E: 26.7Market Cap: ₹60.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

Domestic business: Expected to deliver high single-digit growth (~8-9%) with a combination of volume recovery and price increases through NRV (net realizable value), especially post Q2 after DPCO price hikes take effect.
Chronic therapy segment growing faster than the market with 15.8% YoY growth; expected to contribute positively to margins.
Enzene biosimilar and CDMO business projected to grow from Rs.260 Crores in FY2024 (up from Rs.160 Crores last year) with aspirations to double sales over the next couple of years; break-even expected next year.
International markets, including the US, showing sustainable growth mainly from existing products and easing price erosion; no reliance on one-off opportunities.
Trade generic and branded segments expected to grow in tandem; trade generics growing faster historically.
Overall, cautious optimism with guidance of 16% EBITDA margin and moderate revenue growth factoring in raw material price softening and cost-saving efforts.

Margin guidance

Category 3

Alkem Laboratories expects domestic business growth in high single digits for FY2024, with double-digit growth seen as challenging currently.
EBITDA margin guidance is maintained at around 16%, with efforts to increase margins by 50 to 100 basis points annually.
Enzene (biosimilars and CDMO segment) is projected to grow to around Rs.260-250 Crores revenue for the year, with break-even expected in the next financial year.
Cost-saving initiatives are ongoing, with Rs.110 Crores factored into the current budget and medium-term goals aiming for Rs.200 Crores savings.
Easing of raw material prices and freight cost reductions may support margin improvement going forward.
International business growth is expected to sustain, supported by a strong Q1 international revenue performance crossing Rs.1000 Crores.
The company plans to launch 2-3 new products annually, supporting growth prospects in both domestic and international markets.

See what Alkem Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any new fundraising through debt or equity in the provided transcript.
The company has a net cash position of Rs. 24 billion and maintains a conservative approach to capital allocation.
Current capital allocation focuses on acquisitions and organic growth, with no immediate plans to revise dividend policy or increase medical representative deployment.
CFO Rajesh Dubey and Sandeep Singh emphasized that if better opportunities arise, the company has resources available, but nothing is planned in the near term.
The discussions around capital expenditure primarily focus on biosimilar investments with annual capex guidance of Rs. 300-350 Crores, largely directed toward biosimilars, not new fundraising.
Overall, the company seems comfortable with its cash and funding position without the need for fresh equity or debt at present.

Order book

The transcript does not provide explicit details on the current or expected order book or pending orders for Alkem Laboratories. However, relevant points related to growth and business outlook include: - Enzene's consolidated top line is expected around Rs. 260 Crores for the year, up from Rs. 160 Crores last year. - Enzene expects to launch 2-3 new products annually, with some launches planned for the next quarter. - Enzene is expected to break even next year, currently running mild losses. - The domestic business is expected to grow in high single digits; acute segment shows about 5.9% growth and chronic about 3.5%. - International business growth, especially in the US, is seeing recovery with a sustainable revenue base, not reliant on one-time opportunities. - Capital expenditure for FY2024 is guided at Rs. 300-350 Crores, majorly for biosimilars. No specific order book or pending order figures are disclosed.

See what Alkem Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Q1 FY2024 capex was approximately Rs. 78-80 Crores.
Annual capex guidance for FY2024 is Rs. 300-350 Crores.
Major portion of the capex is allocated for biosimilar investments.
The capex guidance includes investments in biosimilars along with other ongoing capital expenditures.
No specific mention of new large strategic acquisitions or expansions; company maintains a conservative capital allocation approach.
Management open to deploying cash if better acquisition opportunities arise but currently focused on internal investments, especially in biosimilars and CDMO.
No expansion in medical representative force planned, indicating focus on efficiency and product pipeline rather than salesforce scaling.

Track Alkem Laboratories Ltd — get its next earnings analysis in your feed

How does Alkem Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlkem Laboratories Ltd

Rev 4Mar 3

See where Alkem Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alkem Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alkem Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alkem Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →